These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1090359)

  • 1. Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy.
    Berd D; Cornog J; DeConti RC; Levitt M; Bertino JR
    Cancer; 1975 Apr; 35(4):1050-4. PubMed ID: 1090359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites.
    Cadman E; Farber L; Berd D; Bertino J
    Cancer Treat Rep; 1977 Sep; 61(6):1109-16. PubMed ID: 332346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
    Durant JR; Loeb V; Dorfman R; Chan YK
    Cancer; 1975 Dec; 36(6):1936-44. PubMed ID: 1106833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell cycle agents and cyclophosphamide in the treatment of diffuse histiocytic lymphoma.
    Gomez GA; Stutzman L
    Eur J Cancer (1965); 1978 Oct; 14(10):1051-5. PubMed ID: 361413
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma.
    Sweet DL; Golomb HM; Ultmann JE; Miller JB; Stein RS; Lester EP; Mintz U; Bitran JD; Streuli RA; Daly K; Roth NO
    Ann Intern Med; 1980 Jun; 92(6):785-90. PubMed ID: 6992679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.
    Cabanillas F; Burgess MA; Bodey GP; Freireich EJ
    Am J Med; 1983 Mar; 74(3):382-8. PubMed ID: 6187213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of non-Hodgkin lymphoma: the diffuse types.
    Sweet DL; Ultmann JE
    Antibiot Chemother (1971); 1978; 24():125-33. PubMed ID: 350133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy.
    Schein PS; Chabner BA; Canellos GP; Young RC; DeVita VT
    Cancer; 1975 Feb; 35(2):354-7. PubMed ID: 1089470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of combination chemotherapy of non-Hodgkin's lymphoma.
    Schein PS; Chabner BA; Canellos GP; Young RD; Berard C; DeVita VT
    Br J Cancer Suppl; 1975 Mar; 2():465-73. PubMed ID: 1101932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.
    Fisher RI; DeVita VT; Johnson BL; Simon R; Young RC
    Am J Med; 1977 Aug; 63(2):177-82. PubMed ID: 70170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse histiocytic lymphoma.
    Cadman E; Bertino
    Ann Intern Med; 1977 Feb; 86(2):244-5. PubMed ID: 319729
    [No Abstract]   [Full Text] [Related]  

  • 12. Diffuse histiocytic lymphoma. The need for aggressive restaging.
    Weinerman BH; Levitt M; Babick T
    JAMA; 1977 May; 237(22):2403-4. PubMed ID: 323527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced diffuse histiocytic lymphoma, a potentially curable disease.
    DeVita VT; Canellos GP; Chabner B; Schein P; Hubbard SP; Young RC
    Lancet; 1975 Feb; 1(7901):248-50. PubMed ID: 46388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy.
    Glick JH; McFadden E; Costello W; Ezdinli E; Berard CW; Bennett JM
    Cancer; 1982 Mar; 49(5):840-5. PubMed ID: 7037153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
    McKelvey EM; Gottlieb JA; Wilson HE; Haut A; Talley RW; Stephens R; Lane M; Gamble JF; Jones SE; Grozea PN; Gutterman J; Coltman C; Moon TE
    Cancer; 1976 Oct; 38(4):1484-93. PubMed ID: 791473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
    Morgenfeld MC; Pavlovsky A; Suarez A; Somoza N; Pavlovsky S; Palau M; Barros CA
    Cancer; 1975 Oct; 36(4):1241-9. PubMed ID: 1100220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Hodgkin's lymphoma in children.
    Brecher ML; Sinks LF; Thomas RR; Freeman AI
    Cancer; 1978 May; 41(5):1997-2001. PubMed ID: 348300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
    Schein PS; DeVita VT; Hubbard S; Chabner BA; Canellos GP; Berard C; Young RC
    Ann Intern Med; 1976 Oct; 85(4):417-22. PubMed ID: 61732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.
    Laurence J; Coleman M; Allen SL; Silver RT; Pasmantier M
    Ann Intern Med; 1982 Aug; 97(2):190-5. PubMed ID: 6179448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.